CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4,236 enrolled
Drug / intervention
bicalutamide +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00541047
NCT00541047Phase 3Completed

Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)

University College, London·interventional·Posted Oct 8, 2007·Updated Nov 13, 2023

In Brief

A Phase 3 clinical trial evaluating bicalutamide, goserelin acetate, and 4 other interventions for Gastrointestinal Complications and 3 related conditions. Completed, enrolled 4,236 participants across 58 sites in 2 countries.

Detailed Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy, such as goserelin, leuprolide, or bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with androgen deprivation therapy may kill more prostate cancer cells. PURPOSE: This randomized phase III trial is studying how well giving radiation therapy together with androgen deprivation therapy works in treating patients who have undergone surgery for prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United Kingdom

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 8, 2007
Enrollment StartNov 1, 2007
Primary CompletionJul 27, 2022
TodayJul 2, 2026
Enrollment to primary: 14.7 yearsPosted 18.7 years ago

Interventions

bicalutamidedrug

goserelin acetatedrug

leuprolide acetatedrug

adjuvant therapyprocedure

quality-of-life assessmentprocedure

radiation therapyradiation